Sakar Healthcare Limited — Dexamethasone Exporter Profile
Indian Pharmaceutical Exporter · #4 for Dexamethasone · $2.9M export value · DGFT Verified
Sakar Healthcare Limited is the #4 Indian exporter of Dexamethasone with $2.9M in export value and 57 verified shipments. Sakar Healthcare Limited holds a 1.6% market share in Dexamethasone exports across 6 countries. The company exports 6 pharmaceutical products worth $16.0M across 4 therapeutic categories.
Sakar Healthcare Limited — Dexamethasone Export Profile: Buyers & Destinations
Where Does Sakar Healthcare Limited Export Dexamethasone?
| Country | Value | Shipments | Share |
|---|---|---|---|
| ETHIOPIA | $1.5M | 48 | 94.5% |
| YEMEN, DEMOCRATIC | $50.0K | 1 | 3.2% |
| KENYA | $11.5K | 3 | 0.7% |
| ZIMBABWE | $11.0K | 2 | 0.7% |
| BOLIVIA | $8.1K | 2 | 0.5% |
| BOTSWANA | $6.4K | 1 | 0.4% |
Sakar Healthcare Limited exports Dexamethasone to 6 countries. The largest destination is ETHIOPIA accounting for 94.5% of Sakar Healthcare Limited's Dexamethasone shipments, followed by YEMEN, DEMOCRATIC (3.2%) and KENYA (0.7%). These destinations reflect Sakar Healthcare Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Dexamethasone from Sakar Healthcare Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER | ETHIOPIA | $294.8K | 12 |
| TO THE ORDER OF | ETHIOPIA | $150.0K | 3 |
| AWASH BANK SC | ETHIOPIA | $126.9K | 3 |
| TO THE ORDER OF AWASH BANK S.C | ETHIOPIA | $102.0K | 5 |
| ZAMZAM BANK | ETHIOPIA | $100.0K | 2 |
| TO THE ORDER OF AWASH BANK S.C. | ETHIOPIA | $88.0K | 3 |
| TO THE ORDER OF ZEMEN BANK S.C. | ETHIOPIA | $79.9K | 2 |
| UKEEP PHARMA | YEMEN, DEMOCRATIC | $50.0K | 1 |
| TO THE ORDER OF ADDIS INTERNATIONAL | ETHIOPIA | $50.0K | 1 |
| TO THE ORDER OF ZEMEN BANK S.C., | ETHIOPIA | $50.0K | 1 |
Sakar Healthcare Limited supplies Dexamethasone to 23 buyers globally. The largest buyer is TO THE ORDER (ETHIOPIA), followed by TO THE ORDER OF (ETHIOPIA) and AWASH BANK SC (ETHIOPIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Dexamethasone Export Value and How Much Does Sakar Healthcare Limited Contribute?
India exported $32.1M worth of Dexamethasone through 8,777 shipments from 808 suppliers to 176 countries, serving 2,257 buyers globally. Sakar Healthcare Limited contributes $2.9M to this total, accounting for 1.6% of India's Dexamethasone exports. Sakar Healthcare Limited ships Dexamethasone to 6 countries through 23 buyers.
What Is the Average Shipment Value for Sakar Healthcare Limited's Dexamethasone Exports?
Sakar Healthcare Limited's average Dexamethasone shipment value is $50.0K per consignment, based on 57 shipments totaling $2.9M. The largest destination is ETHIOPIA (94.5% of Sakar Healthcare Limited's Dexamethasone exports).
How Does Sakar Healthcare Limited Compare to Other Indian Dexamethasone Exporters?
Sakar Healthcare Limited ranks #4 among 808 Indian Dexamethasone exporters with a 1.6% market share. The top 3 exporters are MYLAN LABORATORIES LIMITED ($6.1M), SENTISS PHARMA PRIVATE LIMITED ($4.5M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($3.3M). Sakar Healthcare Limited processed 57 shipments to 6 destination countries.
What Dexamethasone Formulations Does Sakar Healthcare Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| DEXAMETHASONE SODIUM PHOSPHATE INJECTION | $510.7K | 15 |
| DEXAMETHASONE SODIUM PHOSPHATE INJECTIONBP (DEXA) (AS PER INVOICE) | $79.9K | 2 |
| DEXAMETHASONE SODIUM PHOSPHATE INJECTIONBP 8MG/2ML DEXA AS PER DOCUMENT | $76.9K | 2 |
| DEXAMETHASONE SODIUM PHOSPHATE INJECTIONBP (DEXA) (AS PER INVOICE)VLS | $72.0K | 3 |
| DEXAMETHASONE SODIUM PHOSPHATE INJECTIONBP 8MG/2ML (AS PER INVOICE)VLS | $56.6K | 3 |
| Dexamethasone Sodium Phosphate Injection | $50.0K | 1 |
| DEXAMETHASONE - 4MG/ML IN 2ML AMPOULE IN | $50.0K | 1 |
| DEXAMETHASONE SODIUM PHOSPHATE INJECTION8MG/ML DEXAAS PER DOCUMENT | $50.0K | 1 |
| DEXAMETHASONE SODIUM PHOSPHATE INJECTIONBP 4MG/ML DEXA AS PER DOCUMENT | $50.0K | 1 |
| DEXAMETHASONE SODIUM PHOSPHATE INJECTIONBP DEXA AS PER DOCUMENT | $50.0K | 1 |
Sakar Healthcare Limited exports 28 distinct Dexamethasone formulations including tablets, capsules, syrups, and combination drugs. The top formulation is DEXAMETHASONE SODIUM PHOSPHATE INJECTION with 15 shipments worth $510.7K.
How Does Sakar Healthcare Limited Compare to Nearest Dexamethasone Exporters?
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $3.3M | 65 | 5 | $50.0K |
| 8 | EUGIA PHARMA SPECIALITIES LIMITED | $3.2M | 64 | 1 | $50.0K |
| 4 | SAKAR HEALTHCARE LIMITED ★ | $2.9M | 57 | 6 | $50.0K |
| 12 | ZYDUS LIFESCIENCES LIMITED | $2.6M | 154 | 6 | $16.8K |
| 1 | DR.REDDY'S LABORATORIES LTD | $2.3M | 46 | 1 | $50.0K |
Sakar Healthcare Limited ranks #4 among 808 Indian Dexamethasone exporters. Average shipment value of $50.0K compared to the market average of $39.8K. The closest competitors by value are SUN PHARMACEUTICAL INDUSTRIES LIMITED and EUGIA PHARMA SPECIALITIES LIMITED.
Which Indian Ports Ship Dexamethasone Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 1,214 | 13.8% |
| SAHAR AIR CARGO ACC (INBOM4) | 1,121 | 12.8% |
| NHAVA SHEVA SEA (INNSA1) | 748 | 8.5% |
| DELHI AIR CARGO ACC (INDEL4) | 509 | 5.8% |
| DELHI AIR | 476 | 5.4% |
| JNPT/ NHAVA SHEVA SEA | 472 | 5.4% |
| Bombay Air | 327 | 3.7% |
| JNPT | 320 | 3.6% |
Geopolitical & Trade Policy Impact on Sakar Healthcare Limited's Dexamethasone Exports
Sakar Healthcare's export operations are influenced by various geopolitical factors. The ongoing Israel-Iran tensions have disrupted Red Sea shipping routes, leading to increased freight costs and potential delays. The Pharmaceuticals Export Promotion Council of India estimates that the domestic pharma industry could face losses between ₹2,500 crore and ₹5,000 crore due to these disruptions. (medicaldialogues.in) As a company with significant export activities, Sakar may need to explore alternative logistics strategies to mitigate these challenges.
In the United States, recent tariff policies have introduced uncertainties for Indian pharmaceutical exporters. While health products have been exempt from U.S. tariffs, there have been threats to impose significant increases to encourage domestic production. This situation necessitates vigilance from companies like Sakar to adapt to potential policy shifts. (lemonde.fr)
European Union regulatory changes, such as the Falsified Medicines Directive, impose stringent compliance requirements on pharmaceutical imports. Sakar's recent marketing authorizations in Europe suggest a proactive approach to meeting these standards, enhancing its competitiveness in the EU market. (prysm.fi)
Sakar Healthcare Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is crucial for Indian pharmaceutical exporters. Sakar Healthcare's successful acquisition of marketing authorizations in Europe indicates adherence to Good Manufacturing Practices (GMP) and other regulatory requirements. Additionally, the company's development of in-house APIs and obtaining Written Confirmations reflect a commitment to quality and regulatory compliance. (prysm.fi)
About Sakar Healthcare Limited
Sakar Healthcare Limited exports 6 products worth $16.0M. Beyond Dexamethasone, top products include Cefixime, Ceftriaxone, Heparin, Flucloxacillin, Diazepam. View the complete Sakar Healthcare Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Dexamethasone — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Dexamethasone shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Sakar Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 57 individual customs records matching Sakar Healthcare Limited exporting Dexamethasone, covering 28 formulations to 6 countries via 23 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 176+ countries, 2,257+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Dexamethasone Export Data from Sakar Healthcare Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Sakar Healthcare Limited's Dexamethasone exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Sakar Healthcare Limited
Full Company Profile →
6 products · $16.0M total trade · 4 categories
Dexamethasone Stats
Company Overview
Top Products by Sakar Healthcare Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Sakar Healthcare Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Dexamethasone. For current shipment-level data, contact TransData Nexus.